| COMPOSITION | |
|---|---|
| K-GLIM-Trio 1mg Tablets | |
| Each Uncoated Bilayared Tablet Contains: | |
| Metformin Hydrochloride IP (in sustained release form) | 500 mg |
| Voglibose IP | 0.2 mg |
| Glimepiride IP | 1 mg |
| K-GLIM-Trio 2mg Tablets | |
| Each Uncoated Bilayared Tablet Contains: | |
| Metformin Hydrochloride IP (in sustained release form) | 500 mg |
| Voglibose IP | 0.2 mg |
| Glimepiride IP | 2 mg |
| INDICATIONS | |
| K-GLIM-Trio Tablets are indicated for the treatment of type 2 diabetes when diet, exercise and dual combination therapy do not result in adequate glycemic control. | |
| DOSAGE AND ADMINISTRATION | |
| Oral: Adults: Initiate dose with one tablet once daily, and gradually titrate to twice daily after assessing the therapeutic response. Or, as prescribed by the physician. Maximum recommended daily doses of individual ingredients: Metformin: 2 g in divided dosage. Voglibose: 1.8 mg in divided dosage. Glimepiride: 8 mg in 1 or 2 divided dosage. | |
| HOW SUPPLIED | |
| 10 Tablets per strip. | |
